Marks Group Wealth Management Inc Cuts Stock Holdings in IDEXX Laboratories, Inc. $IDXX

Marks Group Wealth Management Inc reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 33.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,286 shares of the company’s stock after selling 2,686 shares during the quarter. Marks Group Wealth Management Inc’s holdings in IDEXX Laboratories were worth $2,970,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of IDXX. Illinois Municipal Retirement Fund lifted its stake in shares of IDEXX Laboratories by 1.8% in the 1st quarter. Illinois Municipal Retirement Fund now owns 6,616 shares of the company’s stock valued at $3,717,000 after acquiring an additional 120 shares during the last quarter. Geneos Wealth Management Inc. grew its position in IDEXX Laboratories by 2,309.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 5,928 shares of the company’s stock worth $3,331,000 after acquiring an additional 5,682 shares during the last quarter. Sanctuary Advisors LLC increased its stake in IDEXX Laboratories by 12.8% in the 1st quarter. Sanctuary Advisors LLC now owns 14,364 shares of the company’s stock worth $8,071,000 after purchasing an additional 1,628 shares during the period. Checchi Capital Advisers LLC increased its stake in IDEXX Laboratories by 22.7% in the 1st quarter. Checchi Capital Advisers LLC now owns 702 shares of the company’s stock worth $394,000 after purchasing an additional 130 shares during the period. Finally, Retirement Planning Group LLC bought a new stake in IDEXX Laboratories in the first quarter valued at approximately $273,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 3.0%

Shares of NASDAQ IDXX opened at $557.02 on Thursday. The firm has a fifty day simple moving average of $554.27 and a two-hundred day simple moving average of $600.97. IDEXX Laboratories, Inc. has a 12 month low of $506.91 and a 12 month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $43.94 billion, a PE ratio of 41.02, a price-to-earnings-growth ratio of 2.96 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the previous year, the firm posted $2.91 EPS. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on IDXX. Wall Street Zen lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday. Citigroup started coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Weiss Ratings cut shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Tuesday. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Finally, UBS Group cut their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.